Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025

CITIUS ONCOLOGY, INC.

2025-Q3 EPS reported -$0.28

Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.
LYMPHIR commercial launch planned for Q4 2025; launch supplies and distribution agreements in place.
Raised $12.5M gross from parent equity offerings in Q3; Citius Oncology raised additional $9M in July 2025.
On July 17, 2025, closed public offering with net proceeds of approximately $7.4M.
Cash and cash equivalents were $112 as of June 30, 2025, subsequently improved by July financings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.